Mobile

A trial to determine if rifaximin is more efficient than placebo in treating systemic inflammation and neutrophil (white blood cells) malfunction in patients with cirrhosis and chronic hepatic encepha...

Update Il y a 4 ans
Reference: EUCTR2013-004708-20

A trial to determine if rifaximin is more efficient than placebo in treating systemic inflammation and neutrophil (white blood cells) malfunction in patients with cirrhosis and chronic hepatic encephalopathy

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To test if rifaximin reduces neutrophil spontaneous oxidative burst ex vivo in patients with cirrhosis and chronic hepatic encephalopathy after 30 days.

Inclusion criteria

  • Cirrhosis and chronic hepatic encephalopathy

Links